NanoVibronix Announces CEO Transition TYLER, TEXAS

Announces CEO Transition

TEXAS - June 4, 2025 - NanoVibronix, Inc. (NASDAQ: NAOV) ("NanoVibronix" or the "Company"), a

medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer,

effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"),

a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the

Company's Board of Directors as a director. His continued service will support governance continuity at the Board level.

previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue, a privately-held company

recognized for its innovative enteral feeding solutions. This strategic transaction combined the strengths and complementary capabilities

of both organizations, establishing a robust platform for accelerated growth, operational synergies and expanded reach within the global

medical device market.

Fashek, Chairman of the Board, commented, "Brian has been an integral part of NanoVibronix's success, driving product innovation

and spearheading initiatives to expand distribution and commercialize our unique therapeutic solutions. His dedication and leadership

have helped to lay a solid foundation for the Company's future. On behalf of the Board, I want to sincerely thank Brian for his

service and enduring commitment to the Company."

Besser, the newly appointed CEO of NanoVibronix, stated, "I am honored to step into the role of CEO at such a pivotal time in the

Company's journey. With the recent strategic combination of NanoVibronix and ENvue, I believe we are well-positioned to capitalize

on new market opportunities, enhance our product portfolio and drive long-term stockholder value. I look forward to working with the

Board and our talented team to continue the Company's legacy of innovation and success."

Murphy commented, "It has been a tremendous privilege to lead NanoVibronix and collaborate with such a talented and dedicated team.

I am immensely proud of what we have accomplished together. With Doron at the helm, I am confident in the Company's continued progress

and future achievements. I am committed to supporting Doron and the Board as we transition into this exciting next chapter."

Board of Directors reaffirms its commitment to advancing the Company's strategic vision and maximizing the potential of its product

offerings. NanoVibronix will maintain its focus on the full-scale commercialization of its existing technologies while continuing to

develop innovative medical solutions that deliver exceptional value to patients, providers and stockholders.

Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and

home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct

technology platforms:

/ ENvue aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical

usability, and technology innovation across a range of healthcare environments.

press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"

"may," "will," "plans," "expects," "anticipates," "projects,"

"predicts," "estimates," "aims," "believes," "hopes," "potential,"

or similar words. These forward-looking statements include, but are not limited to: statements regarding market interest in the Company's

technology, including the ENvue System, and future expectations for strategic growth. Forward-looking statements are not guarantees of

future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which

are beyond the Company's control and cannot be predicted or quantified; consequently, actual results may differ materially from

those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance

of the Company's existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in

product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations

in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare

regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the

risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities

and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,

and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The

Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events,

or otherwise, except as required by law.

Maas, Managing Principal